IP Library Granted Patent US 9,527,072
Granted Patent B2
US 9,527,072 · App. 14/266,873 · Granted Dec 27, 2016

Purification of metals

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,527,072
App. No.
14/266,873
Granted
Dec 27, 2016
Kind
B2
Abstract

A solid composition comprises: MnO 2 ; and a compound represented by the general formula (I) wherein: R is a polymer; each Y is independently a hydrogen or a negative charge; Z is either hydrogen or is not present; each n is independently 1, 2, 3, 4, 5 or 6; wherein the MnO 2 is bound to the compound of formula (I) so as to coat the surface thereof. Such a composition may be used for the separation of polyvalent metal species, such as Mo, from one or more accompanying impurities.

Claims (38)

1. An apparatus for separating a polyvalent metal species from one or more accompanying impurities comprising at least one vessel, the vessel having an inlet for the introduction of a solution containing the polyvalent metal species, and an outlet for the elution of components of the solution, the vessel being provided with a solid composition comprising:

MnO 2 and a compound of Formula (I)

wherein:

R is a polymer;

each Y is independently a hydrogen or a negative charge;

Z is either hydrogen or is not present;

each n is independently 1, 2, 3, 4, 5 or 6; and

wherein at least 50% of the surface of the compound of Formula (I) is coated with MnO 2 .

2. The apparatus of claim 1 , wherein the vessel is in the form of a column.

3. The apparatus of claim 1 , wherein the apparatus comprises two vessels in the form of a first column and a second column, wherein the first column is connected to the second column so that an eluate from the first column enters the second column.

4. The apparatus of claim 3 , wherein the solid composition of the first column is a particulate, the particulate comprising particles having a size of about 100 to about 200 mesh.

5. The apparatus of claim 3 , wherein the solid composition of the first column is a particulate, the particulate comprising particles having a size of about 100 to about 200 mesh and the solid composition of the second column is a particulate, the particulate comprising particles having a size of about 200 to about 400 mesh.

6. The apparatus of claim 1 , wherein the inlet is configured downstream from a radioisotope generation facility.

7. The apparatus of claim 6 , wherein the radioisotope generation facility is a Mo-99 radioisotope generation facility.

8. The apparatus of claim 1 , wherein the outlet is connected to a collection vessel.

9. The apparatus of claim 1 , wherein the outlet is connected to a further purification apparatus.

10. The apparatus of claim 1 , wherein R is a copolymer.

11. The apparatus of claim 1 , wherein R is a copolymer of styrene and divinylbenzene or derivatives thereof.

12. The apparatus of claim 1 , wherein R is a crosslinked polystyrene.

13. The apparatus of claim 1 , wherein the solid composition of the vessel is a particulate, the particulate comprising particles of between about 0.1 mm and 0.5 mm in size.

14. The apparatus of claim 1 , wherein the polyvalent metal species is Mo.

15. The apparatus of claim 1 , wherein the polyvalent metal species is a radioactive isotope.

16. The apparatus of claim 1 , wherein the polyvalent metal species is Mo-99.

17. The apparatus of claim 1 , wherein R is chosen from a copolymer of styrene and divinylbenzene and a crosslinked polysterene and n is equal to 1.

18. A solid composition comprising MnO 2 and a compound of Formula (I)

wherein:

R is a polymer;

each Y is independently a hydrogen or a negative charge;

Z is either hydrogen or is not present;

each n is independently 1, 2, 3, 4, 5 or 6; and

wherein at least 50% of the surface of the compound of Formula (I) is coated with MnO 2 .

19. The composition of claim 18 , wherein R is a copolymer.

20. The composition of claim 18 , wherein R is a copolymer of styrene and divinylbenzene or derivatives thereof.

21. The composition of claim 18 , wherein R is a crosslinked polystyrene.

22. The composition of claim 18 , wherein at least 60% of the surface of the compound of Formula (I) is coated with MnO 2 .

23. The composition of claim 18 , wherein at least 75% of the surface of the compound of Formula (I) is coated with MnO 2 .

24. The composition of claim 18 , wherein at least 90% of the surface of the compound of Formula (I) is coated with MnO 2 .

25. The composition of claim 18 , wherein R is chosen from a copolymer of styrene and divinylbenzene and a crosslinked polystyrene, n is equal to 1, and at least 90% of the surface of the compound of Formula (I) is coated with MnO 2 ; and wherein the composition is a particulate comprising particles of between about 0.1 mm and 0.5 mm in size.

Assignments (4)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 039237, FRAME 0147 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0902 →
RELEASE OF SECURITY INTEREST Recorded Jan 31, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: MALLINCKRODT NUCLEAR MEDICINE LLC
Reel/Frame 041131/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2016
From: MALLINCKRODT LLC
To: MALLINCKRODT NUCLEAR MEDICINE LLC
Reel/Frame 039149/0234 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Jul 1, 2016
From: MALLINCKRODT LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 039237/0147 →